A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: The Finnish Ovarian Cancer (FINOVA) study
- 30 September 2006
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (14), 2196-2199
- https://doi.org/10.1016/j.ejca.2006.03.021
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and CyclophosphamideJournal of Clinical Oncology, 2006
- Relevance of high-dose chemotherapy in solid tumoursCancer Treatment Reviews, 2005
- High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 2005
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)JNCI Journal of the National Cancer Institute, 2004
- High dose chemotherapy in ovarian cancerInternational Journal of Gynecologic Cancer, 2001
- High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term resultsBone Marrow Transplantation, 2001
- High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term resultsBone Marrow Transplantation, 2000
- Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group studyAnnals of Oncology, 1996
- Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancerEuropean Journal Of Cancer, 1995
- A Phase II Trial of High-Dose Mitoxantrone, Carboplatin, and Cyclophosphamide with Autologous Bone Marrow Rescue for Recurrent Epithelial Ovarian Carcinoma: Analysis of Risk Factors for Clinical OutcomeGynecologic Oncology, 1995